Abstract 6022
Background
Lung cancer is the first cause of cancer related deaths. RCAS1 (Receptor-binding Cancer Antigen expressed on SiSo cells) is a protein that is expressed in different types of cancer and seems to be involved in the process of the tumour cells’ escape from the immune system surveillance (immunoescape). CD3 (cluster of differentiation CD3), is an antigen that is part of the T cell receptor (TCR) complex on a mature T lymphocyte. Tumor infiltrating lymphocytes (TILs) have been correlated with patients’ survival in several neoplasms.
Methods
The aim of this study was to evaluate the clinical importance of RCAS1 and CD3 expression in non-small cell lung cancer (NSCLC). Tissue microarrays of tumor specimens from 112 patients with newly diagnosed NSCLC were constructed. The sections were stained with monoclonal antibodies against RCAS1, Ki-67 and CD3 using immunohistochemistry and they were studied through classical pathological evaluation and computerized image analysis. Correlations among RCAS1, Ki-67 and CD3 expression, clinicopathological variables and survival were analyzed. In all cases p-value ≤ 0.05 was considered significant.
Results
112 patients were included in this study with mean age 63.6 years old and 83% were males. RCAS1 expression was higher in grade III tumors comparing with grade I (p = 0.004) and grade II (p = 0.005) regardless of the histological type and in adenocarcinomas with lymphovascular invasion (p = 0.014). A positive correlation between RCAS1 and Ki-67 levels was observed (p = 0.002). There was an inverse correlation of overall survival with RCAS1 and Ki-67 levels and patients with higher expression of RCAS1 or Ki-67 had a significantly shorter survival. Also, an inverse correlation between RCAS1 expression and the percentage of CD3(+) TILs was found. Finally, a positive correlation between the percentage of CD3(+) TILs and the patients’ overall survival (p = 0.094) was observed.
Conclusions
CD3 expression was negative correlated with RCAS1 and positive with overall survival in patients with NSCLC. RCAS1 could be a useful biomarker indicating tumor aggressiveness and immunoescape of cancer cells. Further studies needed to elucidate the possible role of RCAS1 as a biomarker in immunooncology era.
Clinical trial identification
Legal entity responsible for the study
Medical School, National and Kapodistrian University of Athens.
Funding
Has not received any funding.
Editorial Acknowledgement
Hellenic Society of Medical Oncology (HeSMO).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract